Prevention is the best medicine: Apply the cyber kill chain

Innovation continues to be a primary driver of value in pharmaceutical research. However, simultaneously, research budgets are coming under ever-increasing pressure. As a consequence, pharma is moving toward a so-called open research model, one that dispenses with recurrent fixed costs in favor of a more flexible and dynamic external “spend.” By adopting this model, pharma could tap into innovation outside their walls. In this webinar, case studies will be presented highlighting the value of such collaborations, while focusing on discovery campaigns that employ highly relevant functional assays.

In order to keep competitive, pharma firms and their partners must keep current with the latest developments in drug delivery.

Pharmaceutical and biotechnology companies value streamlined services from early-phase development to clinical supply services to commercialization. These services not only provide with improved efficiencies, such as the ease of transition from one development phase to the next, but also remove the challenges of dealing with multiple vendors when transitioning into clinical supplies and commercial availability.

Concentration/Ultra-filtration (CUF) membranes are used extensively in biopharmaceutical operations. A typical purification platform may incorporate two to six CUF steps though out the downstream process.